
Opinion|Videos|July 24, 2024
Insights from the TROPION-Lung05 Trial at ASCO 2024
Author(s)Jason Porter, MD
Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.
Advertisement
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on intracranial overall response rate in the TROPION-Lung05 trial with Dato-DXd in patients with brain metastasis from NSCLC.
- What are your key takeaways from this study and how will this impact the treatment of patients with brain metastasis from NSCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5